title: Human steroidogenesis: implications for controlled ovarian stimulation with exogenous gonadotropins.
abstract: In the menstrual cycle, the mid-cycle surge of gonadotropins (both luteinising hormone [LH] and follicle-stimulating hormone [FSH]) signals the initiation of the periovulatory interval, during which the follicle augments progesterone production and begins to luteinise, ultimately leading to the rupture of the follicle wall and the release of an oocyte. The administration of gonadotropins in controlled ovarian stimulation (COS) leads to supraphysiological steroid concentrations of a very different profile compared with those seen during natural cycles. It has been suggested that these high steroid concentrations cause alterations in endometrial development, affecting oocyte viability in assisted reproductive technology. Furthermore, it has been proposed that elevated progesterone levels have a negative effect on the reproductive outcome of COS. This may arise from an asynchrony between embryo stage and endometrium status at the window of implantation. The regulation of progesterone production by the developing follicles during COS is a complicated interplay of hormonal systems involving the theca and granulosa cells, and the effect of the actions of both LH and FSH. The present paper reviews current knowledge of the regulation of progesterone in the human ovary during the follicular phase and highlights areas where knowledge remains limited. In this review, we provide in-depth information outlining the regulation and function of gonadotropins in the complicated area of steroidogenesis. Based on current evidence, it is not clear whether the high levels of progesterone produced during COS have detrimental effects on fertility.
authors.affiliation: Laboratory of Reproductive Biology, University Hospital of Copenhagen, Copenhagen, Denmark. claus.yding.andersen@regionh.dk.
authors.forename: Claus Y
authors.initials: CY
authors.lastname: Andersen
authors.affiliation: Global Medical Affairs, EMD/Merck Serono, One Technology Place, Rockland, MA, 02370, USA. diego.ezcurra@emdserono.com.
authors.forename: Diego
authors.initials: D
authors.lastname: Ezcurra
mesh_terms: D000818:Animals; D019317:Evidence-Based Medicine; D005260:Female; D043373:Follicle Stimulating Hormone, Human / Q000009:adverse effects / Q000235:genetics / Q000378:metabolism / Q000494:pharmacology; D006801:Humans; D007247:Infertility, Female / Q000378:metabolism / Q000628:therapy*; D007986:Luteinizing Hormone / Q000009:adverse effects / Q000235:genetics / Q000378:metabolism / Q000494:pharmacology; D008954:Models, Biological; D010053:Ovary / Q000187:drug effects* / Q000201:enzymology / Q000378:metabolism; D010060:Ovulation / Q000187:drug effects / Q000378:metabolism; D010062:Ovulation Induction / Q000009:adverse effects / Q000379:methods*; D011374:Progesterone / Q000819:agonists / Q000378:metabolism*; D011994:Recombinant Proteins / Q000009:adverse effects / Q000378:metabolism / Q000494:pharmacology
chemical_list: D043373:Follicle Stimulating Hormone, Human; D011994:Recombinant Proteins; D011374:Progesterone; D007986:Luteinizing Hormone